Earnings
Puma Biotechnology Lifts 2026 Profit Outlook To $20 Million-$22 Million, Vows More Cost Cuts If Needed
The cancer-drug maker raised its 2026 net income guidance even as new patient starts for Nerlynx fell and a China royalty cut hit.
Puma Biotechnology (PBYI) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
The cancer-drug maker raised its 2026 net income guidance even as new patient starts for Nerlynx fell and a China royalty cut hit.
SEC Filings
The filing shows Alan Auerbach still holds about 16% of Puma Biotechnology, with no new demands attached to the amendment.